M5 receptor Inhibitors
1 drugsAbout M5 receptor
The M5 receptor is a muscarinic acetylcholine receptor and G protein-coupled receptor (GPCR) involved in various physiological processes via acetylcholine signaling in the nervous system.
The M5 receptor is a potential drug target in respiratory medicine, though no genetic evidence currently links it definitively to specific diseases.
Tiotropium bromide is the only FDA-approved drug (small molecule) associated with the M5 receptor, marketed by Lupin for respiratory indications since 2023.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top M5 receptor Drugs
Lupin is the only company with an approved drug targeting the M5 receptor.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in market validation.
M5 receptor Drug Modality Landscape
Modalities
Routes of Administration
M5 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing treatments.
M5 receptor Clinical Trials 123 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 12 | 0 | 2 | 100% |
| Phase 2 | 24 | 21 | 3 | 0 | 88% |
| Phase 3 | 44 | 42 | 2 | 0 | 95% |
| Phase 4 | 41 | 38 | 3 | 0 | 93% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M5 receptor Drug Approval Timeline (2012 - 2023)
The first and only drug, tiotropium bromide, was approved in 2023.
Recent approval suggests renewed interest, but limited history indicates uncertainty about long-term market potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 50 clinical trials targeting M5 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities